Helus Pharma Announces Positive Phase 3 Results for HLP003 and Reports Fiscal Q2 2027 Financial Results
Helus Pharma reported positive topline results from its Phase 3 APPROACH study for HLP003 in major depressive disorder and announced key executive leadership changes alongside its fiscal second quarter 2027 financial results.